Compare AbCellera Biologics Inc (ABCL) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Solaredge Technologies Inc — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while Solaredge Technologies Inc trades at $49.98 (market cap $3.22B). The key difference: Solaredge Technologies Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | SEDG | |
|---|---|---|
Market Cap | $2.35B | $3.22B |
Sector | Health | Technology |
52-Week High | $8.12 | $78.51 |
52-Week Low | $2.78 | $24.42 |
Enterprise Value | $1.99B | $3.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
SolarEdge Technologies (SEDG) trades at $52.94, up 1.07% on the day, with a bullish technical signal from moving averages and recent positive momentum in solar stocks. The company reported Q1 2026 earnings that missed expectations, with a net loss of $405.45 million on $1.18 billion revenue. Despite negative profitability metrics, SEDG has beaten earnings estimates in two of the last three quarters. Recent news highlights sector-wide gains driven by AI data center power demand and analyst optimism.
The outlook remains mixed: strong solar industry tailwinds and operational cash flow improvement offer potential upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Analyst consensus is cautious with a $32.11 price target below current levels, reflecting concerns over profitability and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
